State-of-the-art & state-from-the-heart, too. Because Cancer cannot be cured by medicine alone.


Creating an unique interactive environment for clinicians, scientists and industry to work together.

Tata Translational Cancer Research Center (TTCRC) is creating an unique interactive environment for clinicians, scientists and industry to work together. The purpose is to deliver a better future for patients with cancer in India. Our aim is to bridge the translational gap that lies between scientific enquiries made at the bedside and the answering of these questions in the laboratory so that we may deliver solutions back to the clinic.

Our mission is to improve the outcome of patients with cancer in eastern India and establish an environment for the training of the next generation of cancer researchers. TTCRC will focus on translational research, bringing problems from the bedside to the laboratory and solutions back to the bedside. Patients with cancer in India often come late to therapy. Thus early detection and prevention are key aims in our programme. Variations in population genetics, environment and health systems mean that successful therapeutic strategies developed in western countries may not always be optimal for Indian patients. As targeted therapy enters clinical practice, we also need to develop approaches that are the most cost effective in situations where resources are limited. The TMC structure and vision of translational health care offer both an excellent clinical environment and a vibrant research environment.

Clinicians, scientists and industry are developing partnerships at TTCRC/TMC so patients not only benefit from modern affordable cancer therapy but we are able to develop cost-effective models of care for Indian patients. This will be based on innovatively designed clinical studies, 2 biomarker analyses and basic research integrated into a modular research theme (see schematic).


Our initial focus is around the common cancers seen at TMH. The most affordable strategy for India, but the most difficult one to achieve is prevention and early detection. TTCRC will be setting up tools for early detection and prevention and develop a robust platform for clinical studies in cancer. Incorporated in this will be institutional biobanking. The second aim is to devise new diagnostic and prognostic tools for patients currently undergoing therapy. The third aim is to conduct research into the biological variations in the therapeutic response to cancer. Integrated into this model will be teaching and training for a future generation of translational cancer researchers in India. The schematic summarises our approach.

TTCRC is being built on a 2 acre plot close to the Tata Medical Center in Rajarhat in Kolkata. It will be a green interactive state of the art institution, incorporating in its design the heritage of and spirit of Kolkata. In the interim, dedicated laboratory facilities will be available by the end of 2013 on the hospital site. The Wellcome-DBT India Alliance and the Tata Trust have provided initial funding for TTCRC.

At TTCRC/TMC we are building a team of excellence. Professor Usha Menon (currently at University College London) is an internationally recognised researcher in Ovarian Cancer. Dr Mohandas Mallath is a renowned expert in gastrointestinal malignancies. They will lead the research into early diagnosis, prevention and patient tailored therapy. Professor Mammen Chandy is India’s foremost haematologist and Professor Vaskar Saha (currently at University of Manchester) a paediatric oncologist of repute. They will lead the research into biomarkers and developing indigenous therapeutic solution. Professor Saha will be the first Director of TTCRC and is the first recipient of the Wellcome Trust’s Department of Biotechnology India Alliance Margdarshi Award. A number of partnerships are being developed both in India and abroad. Major scientific collaborations are with the Indian Institute of Chemical Biology in Jadavpur, the National Institute of Biomedical Genomics in Kalyani, University of Manchester, University College London and Duke University Medical Center among others.

Informal enquiries may be made to Ms.Sukanya Guha at:

Opportunities now exist for young investigators, both clinical and non-clinical, wishing to develop innovative strategies that will benefit translational medicine with a particular focus in cancer.



75% of the hospital beds have been earmarked for the underprivileged. They receive greatly subsidized care. You can help us make a difference too.